Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical Inc (NASDAQ: MBOT) is a pioneer in micro-robotic medical technologies focused on revolutionizing minimally invasive procedures. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's progress in developing autonomous surgical platforms like the LIBERTY Robotic System and Self-Cleaning Shunt technology.
Discover comprehensive coverage of MBOT's latest press releases, including clinical milestones, regulatory updates, and strategic partnerships. Our curated news collection serves as a centralized resource for tracking advancements in robotic-assisted interventions designed to reduce surgical trauma and improve patient outcomes.
Key updates include developments in patented micro-robotic platforms, financial performance reports, and innovations addressing complex surgical challenges. Bookmark this page to stay informed about MBOT's progress in creating next-generation tools that aim to transform vascular and endoscopic procedures through precision robotics.
Microbot Medical Inc. (Nasdaq: MBOT) has completed a significant GLP animal study for its LIBERTY® Robotic System, the first disposable robotic system aimed at endovascular procedures. Conducted at a top MedTech research lab, the study achieved a successful navigation rate of 92% for the robotic system, while demonstrating no evidence of acute vascular injury. Physicians graded the LIBERTY system highly for usability, indicating a quick setup and easy learning curve. However, the LIBERTY Robotic System is still investigational and has not yet received FDA clearance for use.
Microbot Medical Inc. (Nasdaq: MBOT) has suspended the development of its Self-Cleaning Shunt (SCS) project to focus on the LIBERTY® Robotic System. This strategic shift follows positive developments, including the acquisition of endovascular assets from Nitiloop Ltd. and plans for a First-in-Human trial. The company will explore opportunities for the SCS assets, such as licensing or joint ventures. Microbot is on track with key milestones for the LIBERTY system through 2023, aiming to enhance shareholder value.
Microbot Medical (Nasdaq: MBOT) announced a new patent allowance from the Israeli Patent Office for its LIBERTY® Robotic System, specifically covering its roll assembly mechanism. This expansion of the intellectual property portfolio underscores the company's commitment to developing innovative micro-robotic technologies aimed at improving patient care accessibility. CEO Harel Gadot emphasized the importance of these capabilities in realizing their vision of disposable robotics that enhance healthcare worldwide.
Microbot Medical (NASDAQ: MBOT) has acquired the assets of Nitiloop Ltd., which includes the FDA-cleared NovaCross™ family of microcatheters. This acquisition aims to enhance the LIBERTY® Robotic System's capabilities, promoting robotics in endovascular procedures. The NovaCross™ devices are designed for navigating chronic total occlusions (CTO) and will potentially standardize procedures while increasing access to robotic technology globally. The move opens a significant growth opportunity in the $500 million CTO market, aligning with Microbot's strategic mission for global accessibility in medical technologies.
Microbot Medical Inc. (Nasdaq: MBOT) announced the appointment of Dr. David C. Madoff to its Scientific Advisory Board. Dr. Madoff, a renowned interventional radiologist from Yale School of Medicine, brings extensive clinical research experience that is expected to enhance the company's efforts in advancing the LIBERTY® Robotic System through regulatory phases. His expertise in interventional oncology and numerous publications position him to significantly contribute to Microbot's mission of improving clinical outcomes and accessibility in healthcare.
Microbot Medical (NASDAQ: MBOT) has appointed Dr. Ripal T. Gandhi to its Scientific Advisory Board. Dr. Gandhi, an interventional oncologist with expertise in minimally invasive treatments, aims to enhance the development of Microbot's LIBERTY Robotic System. His extensive experience includes over 100 robotic cases and innovation in interventional robotics, providing valuable insights to the team. This recruitment aligns with Microbot's strategy to strengthen its advisory network and advance its micro-robotic technologies, aimed at improving patient outcomes.
Microbot Medical Inc. (Nasdaq: MBOT) has announced that renowned interventional radiologist Vincent Vidal, M.D., PhD, has joined its Scientific Advisory Board. Dr. Vidal, recognized for his expertise in embolization techniques, aims to leverage his experience to advance the LIBERTY® Robotic System. His previous successful pre-clinical trial for the system has inspired this collaboration, which seeks to facilitate regulatory processes and global commercialization. CEO Harel Gadot expressed confidence in Dr. Vidal's contributions towards achieving clinical and financial goals with the system.
Microbot Medical Inc. (NASDAQ: MBOT) announced key developments for its LIBERTY® Robotic System during the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022. CEO Harel Gadot highlighted the commencement of the GLP pre-clinical trial and provided an overview of the company's progress and future plans. Microbot Medical focuses on advanced micro-robotic technologies targeted at improving patient outcomes and accessibility in medical treatments. The presentation is available for viewing on their official website.
Microbot Medical Inc. (Nasdaq: MBOT) has launched its GLP Pre-Clinical Trial for the LIBERTY Robotic System at a renowned MedTech research institute. This trial marks a significant milestone in the company’s journey toward regulatory approvals. CEO Harel Gadot believes that successful feasibility studies will enable them to meet the trial's endpoints and further pursue regulatory approvals in the surgical robotics sector, particularly in endovascular applications. This move underscores Microbot's focus on innovative micro-robotic technologies aimed at enhancing clinical outcomes.
Microbot Medical (NASDAQ: MBOT) announced the appointment of Dr. Sebastian Flacke to its Scientific Advisory Board, enhancing its expertise in the endovascular space. Dr. Flacke, a pioneer in robotic solutions and interventional radiology, will guide the company through crucial regulatory processes and commercialization efforts for the LIBERTY® Robotic System. This system aims to be the first fully disposable endovascular robotic platform, improving patient access globally. CEO Harel Gadot emphasized Dr. Flacke's innovative contributions, signaling strong leadership for future developments.
FAQ
What is the current stock price of Microbot Med (MBOT)?
What is the market cap of Microbot Med (MBOT)?
